skip to main content

HCT 116 p300 WT

HCT 116 p300 WT

Catalogue No.


Cell Line Name

HCT 116 p300 WT

Cell Line Description

The cell line HCT 116 is hemizygous for p300 and is expressed from a single allele and was used to create the knockout clones HCT 116 Clones D10, -F2 and -F5, as described by Iyer et al. 2004.

General Info



Unique to ECACC


Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.


Tissue of Origin



Polygonal epithelium

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 7,10
D3S1358: 12.1,18.1
D5S818: 10,11
D7820: 11,12
D8S1179: 10.1,14.1
D13S317: 10,13
D16S539: 11,13
D18S51: 16,17
D21S11: 29,30
FGA: 18,23
Penta D: 9,13
Penta E: 13,14
TH01: 8,9
vWA: 17,22
The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.


Somatic inactivating mutations of p300 are associated with several cancers including breast, colorectal and gastric cancers. The p300 KO lines, including HCT 116 p300 WT (as control), demonstrate 'aggressive' cancer phenotypes in-vitro, with loss of cell-cell adhesion, defects in cell-matrix adhesion, and increased migration through collagen matrices. p300 is a transcriptional cofactor involved in regulating multiple cellular processes including cell cycle regulation, proliferation, differentiation, apoptosis, DNA damage repair, cell adhesion and properties involved in epithelial to mesenchyme transition.



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin/EDTA solution. Cells are cultured at 37°C, in 95% air and 5% CO₂, and passaged every 3 to 4 days

Culture Medium

McCoy's 5a medium modified, with 10% foetal bovine serum and 2mM L-Glutamine

Growth Mode


Additional Info


Ximbio (formerly known as Cancer Research Technologies Limited)

Country of Origin

United Kingdom

GMO Status

Genetically Modified Organism Class 1 (GMO1)

Hazard Group (ACDP)

Hazard Group (ACDP) 2



Wallace et al. 2015. PLoS Pathog. 11(3):e1004687. PMID: 25803638.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: HCT 116 p300 WT (ECACC 17011214).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.